Cardiovascular effects of l-glutamate microinjection in the supraoptic nucleus of unanaesthetized rats
We report on the cardiovascular effects of l-glutamate ( l-glu) microinjection in the hypothalamic supraoptic nucleus (SON) as well as possible receptor and mechanisms involved. Microinjection of l-glu in 100 nL in the SON caused dose-related pressor and bradycardic responses in unanesthetized rats....
Gespeichert in:
Veröffentlicht in: | Neuropharmacology 2007-05, Vol.52 (6), p.1378-1384 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We report on the cardiovascular effects of
l-glutamate (
l-glu) microinjection in the hypothalamic supraoptic nucleus (SON) as well as possible receptor and mechanisms involved. Microinjection of
l-glu in 100
nL in the SON caused dose-related pressor and bradycardic responses in unanesthetized rats. Responses were markedly reduced in urethane-anesthetized rats. The response to
l-glu 10
nmol was blocked by local pretreatment with 2
nmol of the non-NMDA-receptors antagonist NBQX and not affected by 2
nmol of the selective NMDA-receptor antagonist LY 235959, suggesting that non-NMDA receptors mediate these responses. The pressor and bradycardic response to
l-glu was potentiated by intravenous pretreatment with the ganglion blocker pentolinium and was blocked by intravenous pretreatment with the V
1-vasopressin receptor antagonist dTyr(CH
2)
5(Me)AVP, suggesting involvement of circulating vasopressin in this response. Additionally
l-glu microinjection into the SON increased plasma vasopressin levels (control: 1.3
±
0.2
pg/mL,
n
=
6;
l-glu: 14.7
±
2.3
pg/mL,
n
=
6). In conclusion the results suggest that pressor responses to SON microinjection of
l-glu are caused by activation of non-NMDA glutamate receptors and mediated by vasopressin release into systemic circulation. |
---|---|
ISSN: | 0028-3908 1873-7064 |
DOI: | 10.1016/j.neuropharm.2007.01.011 |